Literature DB >> 22956578

Spleen tyrosine kinase is important in the production of proinflammatory cytokines and cell proliferation in human mesangial cells following stimulation with IgA1 isolated from IgA nephropathy patients.

Min Jeong Kim1, John P McDaid, Stephen P McAdoo, Jonathan Barratt, Karen Molyneux, Esteban S Masuda, Charles D Pusey, Frederick W K Tam.   

Abstract

IgA immune complexes are capable of inducing human mesangial cell (HMC) activation, resulting in release of proinflammatory and profibrogenic mediators. The subsequent inflammation, cellular proliferation, and synthesis of extracellular matrix lead to the progression of IgA nephropathy (IgAN). Spleen tyrosine kinase (SYK) is an intracellular protein tyrosine kinase involved in cell signaling downstream of immunoreceptors. In this study, we determined whether SYK is involved in the downstream signaling of IgA1 stimulation in HMC, leading to production of proinflammatory cytokines/chemokines and cell proliferation. Incubation of HMC with IgA1 purified from IgAN patients significantly increased the synthesis of MCP-1 in a dose-dependent manner. There was also significantly increased production of IL-6, IL-8, IFN-γ-inducible protein-10, RANTES, and platelet-derived growth factor-BB. Stimulation of HMC with heat-aggregated IgA1 purified from IgAN patients induced significantly increased HMC proliferation. Both pharmacological inhibition of SYK and knockdown of SYK by small interfering RNA significantly reduced the synthesis of these mediators and inhibited HMC proliferation. Moreover, positive immunostaining for total and phospho-SYK in glomeruli of kidney biopsies from IgAN patients strongly suggests the involvement of SYK in the pathogenesis of IgAN. To our knowledge, we demonstrate, for the first time, the involvement of SYK in the downstream signaling of IgA1 stimulation in HMC and in the pathogenesis of IgAN. Hence, SYK represents a potential therapeutic target for IgAN.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22956578     DOI: 10.4049/jimmunol.1102603

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

Review 1.  New and emerging therapies for acute and chronic graft versus host disease.

Authors:  LaQuisa Hill; Amin Alousi; Partow Kebriaei; Rohtesh Mehta; Katayoun Rezvani; Elizabeth Shpall
Journal:  Ther Adv Hematol       Date:  2017-11-28

Review 2.  New-generation therapy for ANCA-associated vasculitis.

Authors:  David Jayne
Journal:  Clin Exp Nephrol       Date:  2013-09-07       Impact factor: 2.801

3.  Combined C4d and CD3 immunostaining predicts immunoglobulin (Ig)A nephropathy progression.

Authors:  B Faria; C Henriques; A C Matos; M R Daha; M Pestana; M Seelen
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

Review 4.  Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?

Authors:  F M Rasche; F Keller; W G Rasche; S Schiekofer; A Boldt; U Sack; J Fahnert
Journal:  Clin Exp Immunol       Date:  2016-09-08       Impact factor: 4.330

5.  Update on immunoglobulin a nephropathy. Part II: Clinical, diagnostic and therapeutical aspects.

Authors:  Maurizio Salvadori; Giuseppina Rosso
Journal:  World J Nephrol       Date:  2016-01-06

Review 6.  The Treatment of IgA Nephropathy.

Authors:  Kar Neng Lai; Joseph C K Leung; Sydney C W Tang
Journal:  Kidney Dis (Basel)       Date:  2015-04-15

7.  MiR-29b expression is altered in crescent formation of HSPN and accelerates Ang II-induced mesangial cell activation.

Authors:  Shan Cheng; Chun-Hua Zhu; Ai-Hua Zhang; Song-Ming Huang
Journal:  World J Pediatr       Date:  2019-10-19       Impact factor: 2.764

8.  Transcriptomic and Proteomic Profiling Provides Insight into Mesangial Cell Function in IgA Nephropathy.

Authors:  Peidi Liu; Emelie Lassén; Viji Nair; Celine C Berthier; Miyuki Suguro; Carina Sihlbom; Matthias Kretzler; Christer Betsholtz; Börje Haraldsson; Wenjun Ju; Kerstin Ebefors; Jenny Nyström
Journal:  J Am Soc Nephrol       Date:  2017-06-23       Impact factor: 10.121

Review 9.  IgA nephropathy enigma.

Authors:  Jiri Mestecky; Jan Novak; Zina Moldoveanu; Milan Raska
Journal:  Clin Immunol       Date:  2016-07-18       Impact factor: 3.969

Review 10.  New therapeutic perspectives for IgA nephropathy in children.

Authors:  Alexandra Cambier; Patrick J Gleeson; Héloise Flament; Marie-Bénédicte Le Stang; Renato C Monteiro
Journal:  Pediatr Nephrol       Date:  2020-02-10       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.